156 related articles for article (PubMed ID: 11751474)
41. Higher frequency of DPC4/Smad4 alterations in pancreatic cancer cell lines than in primary pancreatic adenocarcinomas.
Bartsch D; Barth P; Bastian D; Ramaswamy A; Gerdes B; Chaloupka B; Deiss Y; Simon B; Schudy A
Cancer Lett; 1999 May; 139(1):43-9. PubMed ID: 10408907
[TBL] [Abstract][Full Text] [Related]
42. Smad4 silencing in pancreatic cancer cell lines using stable RNA interference and gene expression profiles induced by transforming growth factor-beta.
Jazag A; Ijichi H; Kanai F; Imamura T; Guleng B; Ohta M; Imamura J; Tanaka Y; Tateishi K; Ikenoue T; Kawakami T; Arakawa Y; Miyagishi M; Taira K; Kawabe T; Omata M
Oncogene; 2005 Jan; 24(4):662-71. PubMed ID: 15592526
[TBL] [Abstract][Full Text] [Related]
43. [Pathologic characteristics and evaluation of the pancreatic cancer].
Fukushima N; Mukai K
Gan To Kagaku Ryoho; 2005 May; 32(5):599-604. PubMed ID: 15918557
[TBL] [Abstract][Full Text] [Related]
44. New tumor suppressor found in pancreatic cancer.
O'Brien C
Science; 1996 Jan; 271(5247):294. PubMed ID: 8553063
[No Abstract] [Full Text] [Related]
45. The relationship between loss expression of DPC4/Smad4 gene and carcinogenesis of pancreatobiliary carcinoma.
Tang ZH; Zou SQ; Hao YH; Wang BJ; Yang XP; Chen QQ; Qiu FZ
Hepatobiliary Pancreat Dis Int; 2002 Nov; 1(4):624-9. PubMed ID: 14607700
[TBL] [Abstract][Full Text] [Related]
46. Loss of Smad4 protein expression occurs infrequently in endometrial carcinomas.
Liu FS; Chen JT; Hsieh YT; Ho ES; Hung MJ; Lu CH; Chiou LC
Int J Gynecol Pathol; 2003 Oct; 22(4):347-52. PubMed ID: 14501814
[TBL] [Abstract][Full Text] [Related]
47. Differential proteome analysis of conditioned media to detect Smad4 regulated secreted biomarkers in colon cancer.
Volmer MW; Stühler K; Zapatka M; Schöneck A; Klein-Scory S; Schmiegel W; Meyer HE; Schwarte-Waldhoff I
Proteomics; 2005 Jul; 5(10):2587-601. PubMed ID: 15912508
[TBL] [Abstract][Full Text] [Related]
48. Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses.
Levy L; Hill CS
Mol Cell Biol; 2005 Sep; 25(18):8108-25. PubMed ID: 16135802
[TBL] [Abstract][Full Text] [Related]
49. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1.
Hahn SA; Schutte M; Hoque AT; Moskaluk CA; da Costa LT; Rozenblum E; Weinstein CL; Fischer A; Yeo CJ; Hruban RH; Kern SE
Science; 1996 Jan; 271(5247):350-3. PubMed ID: 8553070
[TBL] [Abstract][Full Text] [Related]
50. The role of chromosome 18 abnormalities in the progression of pancreatic adenocarcinoma.
Sunamura M; Lefter LP; Duda DG; Morita R; Inoue H; Yokoyama T; Yatsuoka T; Abe T; Egawa S; Furukawa T; Fukushige S; Oshimura M; Horii A; Matsuno S
Pancreas; 2004 Apr; 28(3):311-6. PubMed ID: 15084978
[TBL] [Abstract][Full Text] [Related]
51. TGF-beta-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines.
Fink SP; Mikkola D; Willson JK; Markowitz S
Oncogene; 2003 Mar; 22(9):1317-23. PubMed ID: 12618756
[TBL] [Abstract][Full Text] [Related]
52. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas.
Izeradjene K; Combs C; Best M; Gopinathan A; Wagner A; Grady WM; Deng CX; Hruban RH; Adsay NV; Tuveson DA; Hingorani SR
Cancer Cell; 2007 Mar; 11(3):229-43. PubMed ID: 17349581
[TBL] [Abstract][Full Text] [Related]
53. Analysis of the DPC4 gene in gastric carcinoma.
Nishizuka S; Tamura G; Maesawa C; Sakata K; Suzuki Y; Iwaya T; Terashima M; Saito K; Satodate R
Jpn J Cancer Res; 1997 Apr; 88(4):335-9. PubMed ID: 9197522
[TBL] [Abstract][Full Text] [Related]
54. p53 and DPC4 alterations in the bile of patients with pancreatic carcinoma.
Pantalone D; Pelo E; Minuti B; Giotti I; Mazza E; Falchini M; Neri B; Nesi G; Roberta Girardi L; Pulli R; Credi G; Torricelli F
J Surg Oncol; 2004 Dec; 88(4):210-6. PubMed ID: 15565642
[TBL] [Abstract][Full Text] [Related]
55. Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction.
Kuang C; Chen Y
Oncogene; 2004 Feb; 23(5):1021-9. PubMed ID: 14647410
[TBL] [Abstract][Full Text] [Related]
56. Loss of heterozygosity or intragenic mutation, which comes first?
Wilentz RE; Argani P; Hruban RH
Am J Pathol; 2001 May; 158(5):1561-3. PubMed ID: 11337351
[No Abstract] [Full Text] [Related]
57. Mutational analysis of TGF-beta type II receptor, Smad2, Smad3, Smad4, Smad6 and Smad7 genes in colorectal cancer.
Fukushima T; Mashiko M; Takita K; Otake T; Endo Y; Sekikawa K; Takenoshita S
J Exp Clin Cancer Res; 2003 Jun; 22(2):315-20. PubMed ID: 12866583
[TBL] [Abstract][Full Text] [Related]
58. Frequent loss of SMAD4/DPC4 protein in colorectal cancers.
Salovaara R; Roth S; Loukola A; Launonen V; Sistonen P; Avizienyte E; Kristo P; Järvinen H; Souchelnytskyi S; Sarlomo-Rikala M; Aaltonen LA
Gut; 2002 Jul; 51(1):56-9. PubMed ID: 12077092
[TBL] [Abstract][Full Text] [Related]
59. High-throughput drug screening of the DPC4 tumor-suppressor pathway in human pancreatic cancer cells.
Sohn TA; Su GH; Ryu B; Yeo CJ; Kern SE
Ann Surg; 2001 May; 233(5):696-703. PubMed ID: 11323508
[TBL] [Abstract][Full Text] [Related]
60. SEL1L expression in pancreatic adenocarcinoma parallels SMAD4 expression and delays tumor growth in vitro and in vivo.
Cattaneo M; Orlandini S; Beghelli S; Moore PS; Sorio C; Bonora A; Bassi C; Talamini G; Zamboni G; Orlandi R; Ménard S; Bernardi LR; Biunno I; Scarpa A
Oncogene; 2003 Sep; 22(41):6359-68. PubMed ID: 14508516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
